Revenue segments as reported by the company.

Diagnostics

Drug Development

Intercompany eliminations and other

Biopharma Laboratory Services

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative expenses

Amortization of intangibles and other assets

Goodwill and other asset impairments

Restructuring and other charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Labcorp Holdings Inc

Laboratory Corp. of America Holdings operates as a life sciences company, which engages in the provision of vital information to help health professionals make clear and confident decisions. It operates through the Drug Development and Diagnostics segments. The Drug Development segment consists of lead optimization, preclinical safety assessment, analytical services, clinical trials, central laboratories, biomarkers, and companion diagnostics, market access, and technology solutions. The Diagnostics segment includes primary care, women's health, specialty medicine, oncology, ACOs, and hospitals and health systems. The company was founded in 1971 and is headquartered in Burlington, NC.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Labcorp posts strong Q4 results, eyes growth amid strategic moves

Labcorp's Q4 performance reflects resilience and growth potential in Diagnostics and Drug Development
Strategic initiatives and spinoff plans position Labcorp for future success and market leadership
Challenges in cost management and revenue growth require focused strategies for sustainable growth
Opportunities lie in capital deployment, market expansion, and operational enhancements for Labcorp

Labcorp reports strong Q1 results, eyes growth amid challenges

Labcorp's Q1 2023 performance was strong, driven by Diagnostics base business revenue growth and strategic initiatives.
While facing challenges like margin constraints and revenue declines in Drug Development, Labcorp is focusing on sustained growth and market opportunities.
The company's emphasis on digital health, upcoming Investor Days, and robust M&A pipeline showcase a proactive approach to future growth.
Labcorp's cautious optimism for SALSA approval and continued advocacy for legislation position it well for potential impacts and future developments.

Labcorp reports robust Q2 earnings, eyes global expansion opportunities

Labcorp's Q2 performance was strong, with revenue growth and strategic initiatives driving positive results.
Challenges such as supply constraints and margin expectations were addressed, with a focus on capital allocation and growth opportunities.
The company remains optimistic about future prospects, with expansion plans, enhanced disclosures, and consistent guidance for segments.
Investor Day scheduled for September to provide more insights, reflecting Labcorp's commitment to transparency and growth.

Labcorp reports robust Q3 earnings, eyes growth amid regulatory challenges

Labcorp's Q3 performance was strong, with a focus on revenue growth, strategic partnerships, and new test introductions. Despite challenges from regulatory impacts, the company remains optimistic about driving substantial shareholder value through growth opportunities and cost-saving initiatives.

LabCorp reports robust Q4 earnings, eyes growth in strategic areas

LabCorp's Q4 call showcased strong financials, strategic partnerships, and innovative offerings. Challenges include pricing issues in Biopharma and COVID impacts on Diagnostics. Opportunities for growth through capital allocation and focus on larger pharma in Biopharma.

LabCorp reports robust Q1 earnings, eyes margin improvement in 2024

LabCorp's Q1 2024 earnings call highlighted strong financial performance, strategic acquisitions, and plans for margin improvement. Despite challenges in certain business areas, the company remains focused on profitable growth and innovation in specialty testing.

Labcorp reports robust Q2 earnings, eyes growth through innovation

Labcorp's Q2 2024 earnings reflect a strong performance, marked by revenue growth, strategic acquisitions, and innovation in healthcare solutions.
While facing challenges in certain segments, Labcorp's focus on expansion, new tests, and digital solutions positions it well for future growth and market leadership.
With a clear outlook for growth and a commitment to advancing healthcare, Labcorp remains a key player in the diagnostics and biopharma laboratory services industry.

Labcorp reports robust Q3 earnings, eyes growth through strategic partnerships

Labcorp's Q3 2024 performance reflects strong revenue growth and profitability, driven by Diagnostics and Biopharma services.
Despite challenges such as regulatory delays, the company remains focused on strategic growth initiatives and operational efficiency.
With a positive outlook for continued growth, Labcorp's emphasis on partnerships, innovation, and cost-saving measures bodes well for its long-term success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Labcorp Holdings, Inc. engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.

SAN FRANCISCO--(BUSINESS WIRE)-- #Biopharma--Xcell Biosciences Inc. (Xcellbio), an instrumentation company focused on cell and gene therapy applications, today announced it has achieved key milestones in its R&D collaboration with Labcorp, a global leader of innovative and comprehensive laboratory services, aimed at driving innovation in the development and validation of cell and gene therapies. Those milestones include jointly generated results that have supported new intellectual property filings and.

Xcell Biosciences and Labcorp Achieve Key Data Milestones in Cell and Gene Therapy Collaboration

American Express

JD.com

Kroger

McKesson

Olin

Stellantis N.V. 

While the glitz and glamour of the hottest technology firms organically command our attention, investors should earmark some time for researching value stocks to buy. Fundamentally, these under-the-radar ideas offer the potential for significant returns.

The 7 Most Undervalued Value Stocks to Buy Now: August 2023

Labcorp Expands Diagnostic Testing and Laboratory Services in Eastern Massachusetts to Increase Access, Affordability and Standardized Testing Labcorp and Tufts Medicine have entered into an agreement for Labcorp to acquire the Tufts Medicine Outreach Laboratory Business and select operating assets This transaction – an initial component of an envisioned larger strategic partnership – will expand patient specimen collection access in the locations and diverse communities Tufts Medicine proudly serves and will support its inpatient laboratories and academic mission BOSTON and BURLINGTON, N.C. , Aug. 3, 2023 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced an agreement with Tufts Medicine, a leading integrated academic health system in Massachusetts, for Labcorp to acquire the Tufts Medicine outreach laboratory business and select operating assets as a first step toward a larger strategic partnership.

Labcorp Forges Strategic Partnership with Tufts Medicine, Will Acquire Outreach Laboratory Business

BURLINGTON, N.C. , July 31, 2023 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services,  today announced it will host an Investor Day on Thursday, September 14, 2023, in New York City, beginning at 1:00 p.m.

Labcorp to Host Investor Day on September 14, 2023

A rise in organic revenues, acquisitions, net of divestitures and foreign currency translation drive LabCorp's (LH) Q2 revenues.

LabCorp (LH) Q2 Earnings Miss Estimates, Margins Decline

Laboratory Corporation of America Holdings (NYSE:LH ) Q2 2023 Earnings Conference Call July 27, 2023 9:00 AM ET Company Participants Chas Cook – Vice President-Investor Relations Adam Schechter – Chairman and Chief Executive Officer Glenn Eisenberg – Executive Vice President and Chief Financial Officer Conference Call Participants Jack Meehan – Nephron Research Lisa Gill – JPMorgan A.J. Rice – Credit Suisse Eric Coldwell – Baird Brian Tanquilut – Jefferies Kevin Caliendo – UBS Patrick Donnelly – Citi Kieran Ryan – Deutsche Bank Tim Daley – Wells Fargo Securities Operator Good day.

Laboratory Corporation of America Holdings (LH) Q2 2023 Earnings Call Transcript

LabCorp (LH) came out with quarterly earnings of $3.42 per share, missing the Zacks Consensus Estimate of $3.47 per share. This compares to earnings of $4.96 per share a year ago.

LabCorp (LH) Q2 Earnings Lag Estimates

Company Provides Full-Year Guidance Labcorp completed the spin-off of Fortrea on June 30, which is treated as discontinued operations in the historical financials Announced a $1.0 billion accelerated share repurchase program Drove growth through new and expanded healthcare system partnerships Second quarter revenue grew 4% versus last year as the Base Business grew 13%. Results from Continuing Operations for second quarter versus last year: Revenue: $3.0 billion versus $2.9 billion Diluted EPS: $1.74 versus $2.89 Adjusted EPS: $3.42 versus $4.04 Free Cash Flow: $177 million versus $408 million Full-Year 2023 Guidance from Continuing Operations: Adjusted EPS of $13.00 to $14.00 and Free Cash Flow of $0.8 billion to $1.0 billion BURLINGTON, N.C.

Labcorp Announces 2023 Second Quarter Results

Labcorp's Menopause Test and Menopause Support Program provide women with insights to guide their healthcare decisions BURLINGTON, N.C. , July 24, 2023 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today it now offers menopause testing through its Labcorp OnDemand digital health platform.

Labcorp OnDemand Offers Menopause Test to Consumers

LabCorp (LH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate LabCorp (LH) to Report a Decline in Earnings: What to Look Out for

Labcorp's (LH) agreement with Jefferson to build academic collaborations around teaching and developing innovative tests.

Labcorp (LH) Completes Strategic Deal With Jefferson Health

Labcorp's (LH) new agreement with Legacy Health will broaden access to its Diagnostics capabilities and improve services.

Labcorp (LH) Inks Asset Acquisition Deal With Legacy Health

BURLINGTON, N.C. , July 13, 2023 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader in innovative and comprehensive laboratory services, today announced the completion of the previously announced transaction that establishes a strategic relationship with Jefferson Health (Jefferson), the largest health system serving the greater Philadelphia and Southern New Jersey region.

Labcorp Finalizes Strategic Relationship with Jefferson Health

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Should Value Investors Buy Laboratory Corp. of America (LH) Stock?

Agreement Will Expand Access to Labcorp's Diagnostics Capabilities and Improve Services BURLINGTON, N.C. , July 11, 2023 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced that it has entered into an agreement with Legacy Health to acquire select assets of its outreach laboratory business, including laboratory facilities and equipment.

LABCORP AND LEGACY HEALTH AGREE TO COMPREHENSIVE LABORATORY RELATIONSHIP

Laboratory Corporation of America Holdings shares have been hurt by the boom-bust cycle induced by the pandemic. Tough comparables should run off in the coming quarters, as the company is simplifying the business with the Fortrea spinoff. Overall valuations look quite reasonable, amidst modest leverage ratios, which makes me upbeat with earnings growth set to return in the coming quarters.

Laboratory Corporation: Trying To Create Value By Spinning Out Fortrea

LabCorp's (LH) latest partnership will significantly assist patients gain access to cutting-edge, potentially life-saving medication.

LabCorp (LH) Partners With Forge Biologics for Gene Therapies

Labcorp (LH) completes the planned spin-off of Fortrea to operate as an independent clinical development business.

Labcorp (LH) Announces Completion of the Fortrea Spin-off

While the spinoff deal is positive for Labcorp, investors used the opportunity to sell on the news. Labcorp will do a $1 billion stock repurchase program and pay down debt.

Why Shares of Labcorp Dropped Monday

Labcorp LH, +0.35% said Monday it completed the spin-off of Fortrea FTREV, -3.98% as an independent contract research organization (CRO) that specializes in Phase I-IV clinical trial management, patient access and technology solutions to pharmaceutical and biotechnology organizations around the world. Fortrea will begin trading on the Nasdaq starting on Monday under the symbol “FTRE”.

Labcorp spins off Fortrea contract research organization with stock debut on the Nasdaq

Fortrea Holdings Inc

Company completes spin-off from Labcorp and begins trading on Nasdaq under ticker “FTRE” Independent company positioned to capitalize on growth opportunities in phases I-IV clinical trials and patient access, and to extend leading positions in oncology, clinical pharmacology and partnership models DURHAM, N.C., July 03, 2023 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced that it has successfully completed its previously announced spin-off from Labcorp (NYSE: LH).

Fortrea Launches as Leading, Global Contract Research Organization Positioned to Bring Life-Changing Therapies to Patients Faster

BURLINGTON, N.C. , July 3, 2023 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced that it has completed the spin-off of Fortrea, the newly formed independent Contract Research Organization providing Phase I-IV clinical trial management, patient access and technology solutions to pharmaceutical and biotechnology organizations around the world.

Labcorp Completes Spin-off of Fortrea

BURLINGTON, N.C. , June 29, 2023 /PRNewswire/ -- Labcorp (NYSE: LH), a leading global life sciences company, will release its financial results for the second quarter of 2023 before the market opens on Thursday, July 27, 2023.

Labcorp to Announce Second Quarter Financial Results on July 27, 2023

BorgWarner

El Pollo Loco

Seneca Foods

NEW YORK , June 28, 2023 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P SmallCap 600 effective prior to the opening of trading on Thursday, July 6: Fortrea Holdings Inc. (NASD:FTRE) will replace Seneca Foods Corp. (NASD:SENEA). S&P 500 constituent Laboratory Corporation of America Holdings (NYSE:LH) is spinning off Fortrea Holdings in a transaction expected to be completed on July 3.

Fortrea Holdings and PHINIA Set to Join S&P SmallCap 600

Laboratory Corporation has visible headwinds to growth ahead. The company's return on capital employed has lagged behind the required rate of return in the last two periods. Net-net, reiterate that LH stock is a hold, valuation of $221.

News for Labcorp Holdings Inc Stock (LH)